Dan Steiber, RPh, Specialty Pharmacy Times® Editor-In-Chief & Executive Vice President

home / authors / dan-steiber-rph-specialty-pharmacy-timesa-editor-in-chief-and-executive-vice-president

Articles

Community “Specialty” Pharmacy vs the Competition

Community “Specialty” Pharmacy vs the Competition

Dan Steiber, RPh, Specialty Pharmacy Times® Editor-In-Chief & Executive Vice President
September 10th 2018

Given the state of political affairs currently engulfing health care, our industry regularly gets vilified and is frequently a victim of misperception.

Read More

Patients First: Is Specialty Pharmacy in the Blueprint?

Patients First: Is Specialty Pharmacy in the Blueprint?

Dan Steiber, RPh, Specialty Pharmacy Times® Editor-In-Chief & Executive Vice President
July 18th 2018

The meteoric rise in drug spending over the past 10 years has been driven by specialty therapeutics, while spending on traditional therapies has decreased.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD